PACUPod is your trusted source for evidence-based insights tailored to advanced clinical pharmacists and physicians. Each episode dives into the latest primary literature, covering medication-focused studies across specialty pharmacy, and many more. We break down study designs, highlight key findings, and objectively discuss clinical implications—without the hype—so you stay informed and ready to apply new evidence in practice. Whether you’re preparing for board certification or striving for excellence in patient care, PACUPod helps you make sense of the data, one study at a time.
Britany: Welcome back to PACULit! Today, we’re discussing long-term data on deucravacitinib in Japanese patients with moderate to severe plaque psoriasis. Seth, great to have you here to unpack phase 3 evidence from the POETYK PSO-1, PSO-4, and LTE trials.
Seth: Thanks, Britany! Plaque psoriasis is a challenging chronic inflammatory disease affecting about 0.3 to 1% of the Japanese population.
Britany: While several biologics and oral agents exist, long-term safety and efficacy of newer drugs like deucravacitinib are key, especially in ethnically distinct populations where pharmacogenomics may affect response.
Seth: Deucravacitinib’s mechanism is novel. Unlike traditional JAK inhibitors, it selectively targets TYK2, part of the JAK family but distinct in signaling. This selectivity may offer a better safety profile, particularly regarding serious infections and cardiovascular risks.
Britany: The global POETYK PSO-1 and PSO-2 trials showed promising 52-week results, but POETYK PSO-4 focused on Japanese patients. This integrated analysis combines phase 3 RCTs plus a long-term extension, providing up to three years of continuous exposure.
Seth: It’s impressive to have such long-term data in a specific ethnic cohort. The design involved randomized, placebo-controlled phases with deucravacitinib 6 mg once daily. After week 16, placebo patients crossed over to active treatment, then all entered an open-label LTE phase.
Britany: Inclusion criteria were adults with moderate to severe plaque psoriasis: PASI ≥12, sPGA ≥3, and ≥10% body surface area involvement. Patients with other psoriasis types, recent biologic use, or significant comorbidities were excluded.
Seth: This ensured a relatively homogenous population for efficacy and safety assessment. The primary endpoint was PASI 75—at least 75% improvement. Secondary endpoints included sPGA 0 or 1, indicating clear or almost clear skin.
Britany: Safety monitoring included adverse events, serious adverse events, infections including herpes zoster, malignancies, major adverse cardiovascular events, and venous thromboembolism. They used exposure-adjusted incidence rates per 100 person-years to account for varying treatment durations.
Seth: The study included 125 Japanese patients treated with deucravacitinib. Notably, 86.4% had over 24 months of exposure, and 27.2% had more than 36 months—robust for long-term evaluation.
Britany: Median age was about 45 years, with balanced gender distribution. Baseline severity was consistent with moderate to severe psoriasis, and most had no recent biologic therapy, isolating deucravacitinib’s effects.
Seth: Regarding efficacy, the continuous deucravacitinib group from PSO-1 showed PASI 75 rates of 88.9% at year one and 87.5% at year three—remarkable durability.
Britany: sPGA 0/1 rates were sustained too: 74.1% at year one and 66.7% at year three. PSO-4 and placebo crossover groups showed consistent efficacy through three years, reinforcing reproducibility in Japanese patients.
Seth: This durability matters clinically since psoriasis requires long-term management. Sustained high response reduces disease burden and improves quality of life.
Britany: On safety, the exposure-adjusted incidence rate for any adverse event was 188.5 per 100 person-years, expected with chronic treatment and monitoring. Serious adverse events were low at 7.4 per 100 person-years.
Seth: Serious infections were rare at 1.3 per 100 person-years; herpes zoster occurred at 1.6 per 100 person-years. No venous thromboembolism events were reported, and major cardiovascular events were very low at 0.6 per 100 person-years.
Britany: This safety profile is reassuring, especially compared to some JAK inhibitors with concerns about VTE and cardiovascular risks. Two patients had grade 3 or 4 creatine phosphokinase elevations, both resolved without stopping treatment.
Seth: Clinically, monitoring CPK is important, but transient elevations don’t necessarily require stopping therapy unless symptomatic or with other lab abnormalities.
Britany: Also, malignancy incidence was low at 1.0 per 100 person-years, aligning with expected background rates, suggesting no increased risk over three years.
Seth: Deucravacitinib’s selective TYK2 inhibition likely contributes to this favorable safety profile by avoiding broader JAK inhibition that affects multiple cytokine pathways and raises infection and malignancy risks.
Britany: Plus, once-daily oral dosing is convenient and may improve adherence compared to injectable biologics, crucial for sustained control.
Seth: Limitations include the relatively small sample size of 125 patients, which may limit generalizability. Also, beyond the placebo-controlled phase, no active comparator was used, so long-term comparisons to other agents are lacking.
Britany: Attrition bias is possible since continuation rates varied, but consistent efficacy and safety across multiple trials and LTE strengthen the findings.
Seth: Clinically, these data help pharmacists and physicians counsel Japanese patients confidently about long-term deucravacitinib use. Routine monitoring should include liver enzymes and CPK, but low serious adverse event rates are encouraging.
Britany: Regarding drug interactions, deucravacitinib is metabolized mainly via CYP1A2 and CYP2D6, so coadministration with strong inhibitors or inducers requires caution to avoid altered levels.
Seth: Also, patients with hepatic or renal impairment were excluded, so clinical judgment is needed when considering deucravacitinib in these groups.
Britany: Real-world data will further clarify safety and efficacy in broader populations. For now, this integrated analysis provides robust evidence supporting durable efficacy and favorable safety in Japanese patients with moderate to severe plaque psoriasis.
Seth: It’s exciting to see a novel oral agent with sustained benefits and manageable safety over three years—a potential game-changer for patients preferring oral therapy or with biologic contraindications.
Britany: To summarize, deucravacitinib offers a promising long-term option, with PASI 75 rates around 87.5% and sPGA 0/1 near 66.7% at three years. Safety signals remain low, with no new concerns over extended use.
Seth: This supports incorporating deucravacitinib into treatment algorithms for Japanese patients, emphasizing personalized care and ongoing monitoring.
Britany: Thanks for the insightful discussion, Seth. And thank you to our listeners for joining PACULit. Check out the full study by Morita et al. in the Journal of Dermatology for more details.
Seth: Thanks, Britany. Looking forward to our next update exploring cutting-edge clinical literature. Until then, stay curious and keep advancing patient care!
Britany: Take care, everyone!